Stryker Corp. Q4 Profit Rises

Stryker reported strong Q4 results with GAAP earnings of $849 million ($2.20/share) versus $546 million ($1.41) a year ago, and adjusted earnings of $1.726 billion ($4.47/share). Revenue jumped 11.4% to $7.171 billion from $6.436 billion last year. The company issued 2026 guidance for organic net sales growth of 8.0%–9.5% and adjusted EPS of $14.90–$15.10, indicating continued top-line momentum and solid earnings visibility for modeling and positioning.

Analysis

Market structure: Stryker (SYK) is the clear near-term winner — 11.4% revenue growth and 2026 organic guidance of 8.0–9.5% imply sustained demand in orthopedics and surgical equipment, supporting pricing power vs. lower-cost competitors. Direct losers are smaller device specialists and some peers (e.g., ZBH, MDT) that lack Stryker’s mix or margin profile; distributors and medical consumables suppliers see positive pull-through. Cross-asset: stronger results should tighten SYK credit spreads modestly, compress equity IV (short-term), and have negligible commodity/FX impact aside from titanium/stainless-steel inputs.

Risk assessment: Low-probability high-impact tail risks include a large-scale FDA recall or adverse CMS reimbursement changes that could cut amputable device pricing by >5–10% and materially compress margins. Timeline: immediate (days) likely re-rate; short-term (3–9 months) depends on hospital purchasing cycles and any CMS rule changes; long-term (3+ years) hinges on integration/M&A execution and sustaining ~8–9% organic sales. Hidden dependencies: buybacks/M&A can mask organic cadence; watch margins vs. volume tradeoffs.

Trade implications: Favor a directional overweight in SYK driven by guidance — but size and options should control risk; pair trades (long SYK, short ZBH or MDT) capture share shifts. Use 9–15 month call spreads to express upside while selling short-dated calls to harvest IV compression post-earnings. Rotate modestly into Healthcare Equipment from rate-sensitive cyclicals if macro steadies.

Contrarian: Consensus celebrates adjusted EPS but may underweight the GAAP/adjustments gap and reimbursement/regulatory risk; upside could be capped if CMS initiatives surface. Historical parallels: device makers re-rated higher after post-COVID volume rebounds then pulled back on reimbursement/litigation; if buybacks rise >20% y/y without margin improvement, reassess thesis.

Key Decisions for Investors

• Establish a 2–3% long position in SYK within 2 weeks (ticker SYK). Target 15–20% upside over 6–12 months; set a disciplined stop-loss at 8–10% to limit drawdown if guidance momentum fades.
• Implement a relative-value pair: go long SYK 2.0% and short ZBH (Zimmer Biomet) 1.2% or MDT (Medtronic) 1.2% for a 6–12 month trade to capture market-share/pricing outperformance; rebalance if spread narrows <5% absolute or SYK outperforms by >25%.
• Buy a 9–15 month SYK call spread to capture upside with defined risk: buy ATM calls and sell calls ~20% OTM, allocating no more than 0.5% of portfolio to the premium; if SYK rises >20% close or roll for additional upside.
• Sell 30–60 day covered calls or iron-condors after IV compression post-earnings to generate yield (targeting annualized premium 6–8%), but unwind if a CMS reimbursement proposal appears in the next 30–60 days or if share count declines <1% y/y (indicating aggressive buybacks).